Myeloproliferative neoplasm symptoms vary depending on the type a person has. Some symptoms include fatigue, headaches, fever, and unintentional weight loss. There are six types of chronic ...

The symptoms of myeloproliferative neoplasms can be variable and common, which can make it difficult to diagnose if you aren’t looking for the right thing, said Ruben Mesa, MD, FACP, executive ...

Myelofibrosis is a rare blood cancer part of the broader myeloproliferative neoplasms (MPNs) diseases. MPNs have an incidence ...

Myelofibrosis is a rare blood cancer part of the broader myeloproliferative neoplasms (MPNs) diseases. MPNs have an incidence rate of 2.05 new cases per 100,000 Canadians. Currently there are between ...

Among those diagnosed with myeloproliferative neoplasms (MPNs), age, race, marital status, and insurance status can help ...

This is a concise, practical, case-based book documenting examples and scenarios that will help you manage challenging clinical issues for patients with myeloproliferative neoplasms. The editors and ...

Check if you have access via personal or institutional login This is a concise, practical, case-based book documenting examples and scenarios that will help you manage challenging clinical issues for ...

Dr. Bachisio Ziccheddu is the first and presenting author. TP53 Alterations Confer Increased Risk of Leukemic Transformation ...

CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.

The first presentation will describe long term follow-up from patients in Part 1 of the ongoing APEX trial. APEX is a global, open-label, multi-center, two-part Phase 2 clinical trial evaluating the ...